Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With AtezolizumabBusiness Wire • 09/21/20
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents Cantor 2020 Global Virtual Healthcare Conference (Transcript)Seeking Alpha • 09/17/20
Exelixis, Inc.'s (EXEL) CEO Mike Morrissey at BofA Global Healthcare Conference (Transcript)Seeking Alpha • 09/17/20
Exelixis, Inc. (EXEL) Presents at Morgan Stanley Global Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 09/16/20
Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid TumorsBusiness Wire • 09/15/20
Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020Business Wire • 09/14/20
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of CancerBusiness Wire • 09/08/20
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation TechnologyBusiness Wire • 09/08/20
Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/05/20
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell CarcinomaBusiness Wire • 08/24/20
Exelixis' (EXEL) CEO Mike Morrissey on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 08/06/20
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020Business Wire • 07/29/20